Purpose To compare the long‐term safety and efficacy of pattern scanning laser trabeculoplasty (PSLT) and selective laser trabeculoplasty (SLT). Methods This was a retrospective database analysis (Lausanne Laser Trabeculoplasty Registry) of patients having had laser trabeculoplasty (LT) prior to 2017 with a minimum follow‐up of 1 year. Inclusion criteria were age ≥40 years and diagnosis of ocular hypertension (OHT) and open‐angle glaucoma (OAG). Selective laser trabeculoplasty (SLT) eyes were matched to PSLT eyes according to baseline intraocular pressure (IOP), baseline number of ocular hypotensive medications (OHM) and glaucoma diagnosis. Success was defined as an IOP ≤ 20% from baseline or an IOP equal or lower than baseline accompanied by a reduction in OHM. Multivariate regression models were used to study associations between success and baseline clinical parameters. Results From 280 eyes in the database, 81 eyes had PSLT and were matched with 81 SLT eyes (162 patients). Mean age was 69.4 ± 12.1 years, and 56.2% were female. Mean IOP was 18.6 ± 5.3 and 18.2 ± 4.1 mmHg at baseline and 15.9 ± 3.0 and 16.0 ± 3.4 mmHg at 12 months and 15.2 ± 2.7 and 16.2 ± 3.4 mmHg at 24 months, for PSLT and SLT, respectively. 60.5% of PSLT and 65.4% of SLT eyes achieved treatment success (p = 0.20). Number of OHM was 1.0 ± 1.0 and 1.4 ± 1.2, respectively (p = 0.052). Baseline IOP (OR = 1.23, p < 0.01) and number of OHM (OR = 1.67, p < 0.01) were associated with success in both PSLT and SLT, while LT modality was not [OR = 0.81 (0.43–1.53), p = 0.52], and a diagnosis of primary OAG was negatively associated (OR = 0.42, p = 0.04). Conclusion Our study did not find any significant differences between PSLT and SLT in terms of safety and efficacy in patients with OHT and glaucoma. Baseline IOP was associated with higher success rates in both procedures. Additional studies are needed to evaluate the outcomes of PSLT in non‐Caucasian populations and the ability of repeat PSLT to achieve additional IOP reduction.
Background/AimsThe purpose of this study was to assess the difference in outcome between the first-operated eye and the second-operated eye following non-penetrating deep sclerectomy (DS), and to identify potential success predictors for the second eye. MethodsThis single-surgeon, retrospective study analyzed the outcomes of all bilateral nonsimultaneous DS with at least 24 months of follow-up. Its main outcome measure was surgical success, defined as unmedicated intraocular pressure (IOP) ≤ 15 mmHg associated with a relative reduction ≥20%. ResultsIn all, 104 eyes of 52 patients who underwent bilateral (standalone or combined) DS, within a mean of 344.3 ± 526.3 days of each other, were analysed. Post-operatively, mean medicated IOP decreased from 20.7 ± 7.9 (first-operated) and 19.3 ± 6.6 mmHg (second) at baseline (p = 0.107) to 13.8 ± 4.8 ([-33.3%; p < 0.001] first-operated eyes) and 12.7 ± 3.8 mmHg ([-34.2%; p < 0.001] second eyes) after 2 years (p = 0.619). Post-operative IOP and treatments reduction respectively showed fair (r = 0.53) and good (r = 0.71) levels of correlation between fellow eyes. Rates of complete success were comparable between first-operated and second-operated eyes (32.7% and 40.4%, respectively; p = 0.364). At 2 years, among patients whose firstoperated eyes were considered a success, 82.4% of surgeries in second eyes were successful (p=0.001). The odd ratio of a second-operated eye experiencing complete success were 6.32 (p = 0.011) if the first operated eye experienced complete success. ConclusionThe present study demonstrated a strong association between first-operated eyes and secondoperated eyes following DS, in terms of surgical outcomes and IOP reduction. In effect, surgical success in the first-operated eye increases the odds of success in the second eye by 6 folds.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.